Supportive of this paradigm are our findings showing that therapeutic CFTR correction attenuates the HF-associated elevation of systemic and pulmonary S1P concentrations, reduces the frequency of S1P1 positivity on immune cells and, hence, lowers the percentage of lung infiltrating immune cells. This evidence concerns the gene S1PR1 and hydrops fetalis.